News

GBR 1342 is a CD38xCD3 bi-specific antibody based on Glenmark’s proprietary BEAT® platform. GBR 1342 is the second clinical development candidate (following GBR 1302 a HER2xCD3 bi-specific antibody)

In response to the comments, the protocol has been amended and AcelRx plans to initiate the study in the first quarter of 2016. The IAP312 study will include

Under the terms of this agreement, Zymeworks and Kairos also have the option to merge to further integrate their respective platforms, resources and pipelines to accelerate the development

HT-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Akashi Therapeutics CEO Marc Blaustein said: "This agreement

The first four investments under the company’s new focus have gone to BioAlta, NextCure, Cortexyme and 4D Molecular Therapeutcs. The move will allow the recipients to fully explore

Under the risk-sharing agreement, PPD will assist Moderna in its clinical development efforts, including support for investigational new drug strategic planning, as well as for clinical trial design

Under a research collaboration and licensing agreement, the companies will work together to generate and evaluate up to two bispecific NK cell engagers using Innate Pharma’s technology and

In addition, Apogenix and CANbridge have signed an amendment to expand the licensed territories to include Taiwan. Apogenix will continue to develop APG101 in all other territories. An

The company’s latest report states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms